Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pCHIM-p47 Gene Therapy for p47 AR-CGD
NCT05207657Phase 2Recruiting
- Sponsor
- Great Ormond Street Hospital
- Start
- Mar 2023
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of pCHIM-p47phox in chronic granulomatous disease (CGD), sponsored by Great Ormond Street Hospital. Started Mar 2023; status: recruiting.
02
Drugs
pCHIM-p47phox
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05207657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207657.